- Home
- WNC vs LXEO Comparison
WNC vs LXEO Comparison
Compare WNC & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WNC | LXEO |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.2M | 369.8M |
| IPO Year | 2009 | 2023 |
Fundamental Metrics
Financial Performance| Metric | WNC | LXEO |
|---|---|---|
| Price | $7.81 | $5.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $11.00 | ★ $18.44 |
| AVG Volume (30 Days) | ★ 861.1K | 698.6K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.84% | N/A |
| EPS Growth | ★ 179.22 | 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,027,489,000.00 | $654,000.00 |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $14.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $6.63 | $2.51 |
| 52 Week High | $12.94 | $10.99 |
Technical Indicators
Market Signals| Indicator | WNC | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 41.97 |
| Support Level | $7.59 | $4.95 |
| Resistance Level | $9.33 | $6.26 |
| Average True Range (ATR) | 0.34 | 0.43 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 78.97 | 33.83 |
Price Performance
Historical ComparisonAbout WNC Wabash National Corporation
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.